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Abstract
Background—Knowledge of trends in the incidence of and survival after myocardial infarction
(MI) in a community setting is important to understanding trends in coronary heart disease (CHD)
mortality rates.
Methods and Results—We estimated race and gender specific trends in the incidence of
hospitalized MI, case-fatality and CHD mortality from community-wide surveillance and
validation of hospital discharges and of in- and out-of-hospital deaths among 35 to 74 year old
residents of four communities in the Atherosclerosis Risk in Communities (ARIC) Study.
Biomarker adjustment accounted for change from reliance on cardiac enzymes to widespread use
of troponin measurements overtime. Between 1987 and 2008, a total of 30,985 fatal or non-fatal
hospitalized acute MI events occurred. Rates of CHD death among persons without a history of
MI fell an average 4.7 percent per year among men and 4.3 percent per year among women. Rates
of both in- and out-of-hospital CHD death declined significantly throughout the period. Age- and
Correspondence: Wayne Rosamond, PhD, Cardiovascular Epidemiology Program, Department of Epidemiology, Bank of America
Building, 137 E. Franklin Street, Suite 306, Chapel Hill, NC 27514, Tel: 919-962-3230, Fax: 919-966-9800,
Wayne_Rosamond@unc.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Conflict of Interest Disclosures: None
NIH Public Access
Author Manuscript
Circulation. Author manuscript; available in PMC 2013 April 17.
Published in final edited form as:













biomarker adjusted average annual rate of incident MI decreased 4.3 percent among white men,
3.8 percent among white women, 2.9 percent among black women, and 1.5 percent among black
men. Declines in CHD mortality and MI incidence were greater in the second decade (1997–
2008). Failure to account for biomarker shift would have masked declines in incidence,
particularly among blacks. Age-adjusted 28-day case-fatality after hospitalized MI declined 4.2
percent per year among white men and 3.6 percent per year among black men, 2.6 percent per year
among white women, and 2.4 percent per year among black women.
Conclusions—Although these findings from 4 communities may not directly generalize to
blacks and whites in the entire US, we observed significant declines in MI incidence, primarily
due to downward trends in rates between 1997 and 2008.
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Introduction
Recent studies suggest that trends in the incidence rate of myocardial infarction (MI) in the
United States may have changed substantially in the last two decades from relatively stable
rates in the 1980’s and 1990’s 1–4 to significant declines in the new millennium. 5–9 Some
recent studies furthered our understanding of contemporary patterns of MI rates by
examining trends by type of MI (presence or absence of ST-segment elevation) and by
estimating the impact on rates brought about by the introduction of troponin measurements
and new definitions of clinical events. 8, 10–13 Whether or not these recently reported trends
apply similarly across race and gender groups and to what extent changes in biomarkers
account for these trends is less well characterized. 14–15 Although available studies offer
valuable insights into recent trends in the occurrence of MI and mortality due to coronary
heart disease (CHD), additional data on trends in annual incidence of MI and CHD mortality
from other large, geographically and ethnically diverse environments using a common
methodology is needed and can provide valuable insights into disease trends in the
population. The importance of these types of data was emphasized in a recent Institute of
Medicine (IOM) report on cardiovascular disease surveillance needs in the United States. 16
We studied trends in mortality due to CHD and in the incidence of MI with and without a
unique adjustment for changes in biomarkers over time from 1987 through 2008, as well as
trends in short-term (28 day) case-fatality after MI from community surveillance in the
Atherosclerosis Risk in Communities (ARIC) Study.
Methods
Study Population
Since 1987, The ARIC Study 17 has conducted continuous retrospective surveillance of
hospital discharges for MI and deaths due to CHD occurring in or out of the hospital among
residents 35 through 74 years of age in Forsyth County, North Carolina; the city of Jackson,
Mississippi; eight northern suburbs of Minneapolis, Minnesota; and Washington County,
Maryland with a combined study population of approximately 396,000 persons in 2008
(Table 1). Twenty-four percent of the study population was black. The trends reported here
in ARIC blacks and whites in these four communities were of interest, even though the
ARIC design cannot totally separate race effects from regional effects, given that sufficient
numbers of blacks to yield stable estimates were only present in only 2 communities
(Jackson, Mississippi and Forsyth County, North Carolina).
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Identification of Hospitalized MI Events
Hospitalized MIs were identified from electronic discharge lists obtained from all hospitals
serving the four communities (n=31). Trained ARIC staff members abstracted medical
records for possible events, selected on age, residence in the community and discharge code
(International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM]
codes 402, 410–414, 427, 428, and 518.4) through random sampling within discharge code
strata. See supplemental materials for a description of ICD-9-CM codes used to identify
events for investigation and validation. Sampling probabilities varied by race, sex, field
center, and discharge code group and were adjusted periodically. 18–19 Hospitalizations of
community residents that occurred outside the study area were not included, unless
transferred to and discharged from a surveillance hospital. Diagnostic information from the
transferring hospital was included in the validation of events. Information obtained from
medical records included: presence of chest pain, history of MI or other cardiovascular
related conditions, and measures of cardiac biomarkers (total creatinine phosphokinase
(CK), creatinine phosphokinase-myocardial band (CK-MB), lactate dehydrogenase, and
troponin). Copies of up to three electrocardiograms were obtained and sent to the University
of Minnesota Electrocardiographic Reading Center for classification according to the
Minnesota code 20. A standardized computerized algorithm was applied to data on chest
pain, cardiac biomarkers, and electrocardiographic evidence to determine each patient’s
computer MI diagnosis 17. Criteria for each of these three diagnostic elements in the
algorithm remained constant over the study period and are described in detail in the ARIC
Study Surveillance Manual. 19 Cases with disagreements between the computer diagnosis
and discharge diagnosis codes were reviewed by physicians on the ARIC Mortality and
Morbidity Classification Committee (MMCC) for final classification. All eligible
hospitalized events were classified as either definite, probable, suspect, or no MI. 17 Definite
or probable MI was combined to define a MI for analysis unless otherwise specified. MI
events with equivocal or abnormal biomarkers were further classified as non-ST segment
elevation MI (NSTEMI) or ST-segment elevation MI (STEMI) based on the coded
electrocardiograms.
A first (incident) MI was defined as one in a patient for whom the medical record either
stated that there was no history of MI or did not contain any reference to a history of MI.
Recurrent MI was defined as any definite or probable MI for which the medical record
stated a history of MI.
Eligible hospitalizations for which the chart could not be located were deemed
unclassifiable. Because missing hospital records are likely not random and may have
included events that would have been validated as MI had the medical record been available,
we adjusted the trends in hospitalized MI rates in sensitivity analyses to account for this
possible source of bias.
Identification of CHD Deaths
For the period 1987–1998 deaths with underlying cause of death ICD-9-CM codes 250, 401,
402, 410–414, 427–429, 440, 518.4, 798, and 799 were sampled. Beginning in 1999,
ICD-10-CM codes E10–14, I10–I11, I21–25, I46–51, I70, I97, J81, J96, R96, and R98–99
were sampled. Sampling fractions varied by sex, field center, and code group and were
adjusted over time. Deaths among community residents occurring outside the state of
residence were omitted. The number of such deaths was few (10 eligible out of state deaths
in 2008) and stable over time. Deaths in nursing homes, emergency departments, and
hospital admissions of persons dead on arrival were classified as out-of-hospital deaths.
Trained ARIC staff reviewed death certificates that met sampling eligibility criteria. For in-
hospital deaths, medical records were also reviewed. For out-of-hospital deaths, additional
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information was sought from the next of kin and other informants, certifying and family
physicians, and coroners or medical examiners. Using standardized criteria, 17 the MMCC
reviewed these data for deaths and assigned a final diagnosis, with disagreements
adjudicated. Trends in CHD mortality included deaths classified as due to either definite
fatal MI or definite fatal CHD. Due to state regulations that prohibited full investigation of
out-of-hospital deaths in Washington County until 1995, this community was not included in
computation of trends involving CHD death prior to that year.
For fatal CHD events, presence or absence of a history of MI was based on information
obtained from the next of kin and other informants including the certifying physician,
coroner or medical examiner, or from medical records for any eligible hospitalization within
28 days before death. Vital status of hospitalized MI events after discharge was determined
through linkage with National Death Index files and used for computing case fatality
percentages.
Adjustment for Biomarker Change
Dramatic shifts in the use of cardiac biomarkers to diagnose MI occurred between 1987 and
2008 10–11. In the ARIC communities, the proportion of eligible hospitalizations with a
troponin measurement increased from 8% in 1996 to 98% by 2001. Patterns of biomarker
adoption varied by community and by hospital within community. To permit a more
meaningful interpretation of trends in MI, we developed an imputation method that
standardizes the event rates to a consistent usage of cardiac biomarkers. Details of this
method as applied to ARIC Surveillance data are described in supplemental materials and
only briefly described here. We adjusted the event rates that include hospitalized myocardial
infarction for changes in biomarkers by imputing the number of events that would have
occurred in a pre-troponin year (i.e. had troponin not been introduced and other biomarkers
not dropped), and had the distribution of the biomarker usage combinations been the same
across years. The adjustment included both an imputation and a standardization procedure.
First we imputed the distribution of the pre-troponin combinations (i.e. the biomarker usage
combinations that would have occurred in a pre-troponin year) and then imputed the
probability of myocardial infarctions in each of the pre-troponin combinations. We then
standardized the imputed probability of myocardial infarctions, and therefore the number of
events, to the distribution of the pre-troponin combinations in a reference period mimicking
direct adjustment. This was an extension of direct adjustment where the distribution of the
pre-troponin combinations for post-1995 events was imputed, from which the probability of
myocardial infarctions in each of the pre-troponin combinations could be estimated by data
regarding overlaps in troponin use and other biomarkers. The last step was weighting the
pre-troponin combination-specific probability of myocardial infarction by the distribution of
the pre-troponin combinations in the reference period.
To validate our biomarker adjustment method procedure we used ARIC data from 1997–
2008 from ARIC for those events that had (troponic AND other enzymes) whenever they
had “troponin OR other enzymes”, simulating an experiment where hospitals kept collecting
enzyme data as usual while adding troponins. We then completely dropped troponins for
1997–2002, an artificial “pre-troponin era”. In our artificial data we used 2002 as the
standard enzyme group distribution. We estimated age and enzyme distribution-standardized
“true” trends in MI attack rate from the biomarker data without troponins. Next we produced
200 datasets that simulated the dropping of other enzymes when troponin was introduced.
The choice of events from which to drop some enzyme data was random, and was done
independently in each of the 200 simulations. We simulated an increasing proportion over
time of events that had enzymes dropped. With each of these 200 datasets we applied the
biomarker adjustment algorithm to get biomarker adjusted rates and trends for the 4 race sex
groups for the period 1997–2008, and then took the average over the 200 datasets and
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compared with “true trends”. We considered only linear trend. The true age- and enzyme
distribution-adjusted trends were −4.4 and −3.7 for men and women, respectively, whereas
the biomarker-adjusted values averaged over the 200 simulated ARIC-like datasets were
−4.0 and −3.3, very close to the true values.
Statistical Analysis
Sampling probabilities were reviewed periodically and modified over the 22-year
surveillance period for efficiency. Details of the sampling procedure are reported
elsewhere. 18 Our analyses were weighted and standard errors computed by stratified
random sample methodology to reflect the sampling scheme.
Annual event rates per 1000 persons specific for sex, race, and community were computed
based on population denominators estimated using interpolation and extrapolation of 1980,
1990 and 2000 United States Census population estimates. Race-specific rates reported by
sex were adjusted for age by the direct method using the 2000 United States total age-
specific population census counts as the standard. Sex-specific rates reported were similarly
adjusted for age and race. In Tables 2 and 3, we report overall 22-year age-adjusted trends
by gender and race or by gender adjusted additionally for race from linear or quadratic
Poisson regression models. Results by time period are from the quadratic models showing
trends separately for the first (1987 through 1996) and second (1997 through 2008) decade
as the average annual percent change in each time period. Figure 1 shows age- and
biomarker adjusted event rates with both linear and quadratic regression model fits
displayed.
Annual 28-day and one-year case fatality percentages specific for sex and race were
computed based on denominators of those who were hospitalized with a MI or a combined
hospitalized plus fatal CHD event. Race-specific percentages reported by sex were adjusted
for age by the direct method using the ARIC combined hospitalized MI plus fatal CHD
events as the standard. Figure 2 shows age-adjusted 28-day case fatality for hospitalized MI
with both linear and quadratic logistic regression model fits displayed. The statistical
packages SUDAAN Logistic was used for case fatality trends analysis and SUDAAN
Loglink for event rate trends analysis
Results
Between 1987 and 2008, a total of 30,985 fatal or non-fatal hospitalized acute MI events
(based on stratified random sample of 20,075 hospitalizations investigated) occurred among
residents age 35 through 74 years in the four study communities in ARIC (Table 1). Of
these, 69% were in persons with no recorded history of MI. There were an estimated 8158
deaths due to CHD (on the basis of 7063 deaths sampled), including both in-hospital and
out-of-hospital deaths.
The average annual percent age-and race-adjusted decline (95 percent confidence interval
[CI]) in rates of death due to CHD was 5.7 percent (95% CI: −6.1, −5.3) in men and 5.2
percent (95% CI: −5.8, −4.6) in women (Tables 2 and 3). Among men, the decline was non-
linear, with the decline steeper in the latter half of the study period (1997 through 2008) than
in the first 10 years (1987 through 1996), −8.6 percent (95% CI: −9.7, −7.5) per year and
−3.4 percent (95% CI: −4.3, −2.4) per year, respectively (p<0.01). The overall downward
age-adjusted trend in total CHD mortality among men was statistically significant in both
ARIC black men (−3.2 percent (95% CI: −4.1, −2.2) per year) and ARIC white men (−6.5
percent (95% CI: −7.0, −6.1) per year), with the percent decline per year among ARIC white
men generally about twice that of ARIC black men regardless of time period. Of note, is the
statistically significant age-adjusted decline in total CHD mortality rates of 5.3 percent (95%
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CI: −7.5, −3.2) per year among ARIC black men from 1997 through 2008 compared to a
non-statistically significant decline of just 0.9 percent (95% CI: −3.3, 1.5) per year in the
preceding 10 years from 1987 through 1996. Among women, the age- and race-adjusted
trends in total CHD mortality rates were generally similar to those in men (i.e. downward
trends in rates greater in the more recent period (p<0.01)). The age-adjusted trends in CHD
deaths not preceded by a MI history mirrored those of total CHD mortality.
Rates of out-of-hospital and in-hospital mortality due to CHD declined significantly among
both men and women (Tables 2 and 3). Age- and race-adjusted declines in rates of out-of-
hospital mortality due to CHD were smaller in percentage compared to in-hospital CHD
deaths. Adjusted percent declines in both in-hospital and out-of-hospital CHD death rates
were substantially greater in the more recent time period (1997 through 2008) compared to
the previous decade (1987 through 1996).
Among men and women, the age- and biomarker-adjusted rate of combined first
hospitalization for acute MI or fatal CHD among patients with no history of MI had a
significant age-adjusted decline from 1987 to 2008 (Figure 1 and Tables 2 and 3). The
overall age-adjusted trend predicted by the fitted quadratic models in annual incidence rates
showed a decline of 4.9 percent (95% CI: −5.3, −4.5) per year among ARIC white men, 3.9
percent (95% CI: −4.5, −3.4) per year among ARIC white women, 3.5 percent (95% CI:
−4.4, −2.6) per year among ARIC black women, and 1.8 percent (95% CI: −2.6, −1.0) per
year among ARIC black men. The average trend for the two decades separately from
quadratic regressions models show that the decline in incidence of MI and fatal CHD was
generally twice as large in the latter decade compared to the first decade. The difference in
the average annual percent change between the two decades was statistically significant for
ARIC white men and women (p<0.01). However, the trends comparing the first and second
decade among ARIC black men and women did not reach statistical significance (p>0.10).
Nevertheless, age-adjusted declines in biomarker adjusted MI and fatal CHD incidence were
statistically significant in all four race-gender groups in the most recent time period (1996
through 2008).
The age- and biomarker-adjusted incidence of hospitalizations for MI had significant
adjusted declines over the 22-year period. The overall downward trend showed a similar
pattern to the trend in combined incident hospitalized MI and fatal CHD, although a test for
differences in the average change in trends between the decades did not reach statistical
significance. Of note is that among black men and women in ARIC, the lack of a statistically
significant downward trend in first hospitalized MI in the earlier time period transitioned to
significant declines in MI incidence during the more recent period (1997 through 2008), of
−2.5 percent (95% CI: −4.7, −0.4) per year and −3.3 percent (95% CI: −5.8, −0.8) per year,
respectively. An examination of trends in recurrent MI revealed significant declines overall,
with the declines in men in the period 1997 through 2008 greater than in the earlier decade
(p<0.01).
The impact of biomarker change adjustment was particularly notable in investigating trends
within and across race-gender groups (Tables 2 and 3). The statistically significant declines
in incidence of hospitalized MI events among ARIC blacks in the most recent time period
found in the biomarker adjusted rates were masked when shifts in biomarkers were not
considered. For example, the age-adjusted average annual percent change in first
hospitalized MI over the 22-year surveillance period among black men in ARIC showed an
increase of 1.0 percent (95% CI: −0.1, 2.1) per year before accounting for the use of more
sensitive biomarkers. After adjustment for biomarker change over time a significant
downward trend of 1.5 percent (95% CI: −2.7, −0.4) per year was revealed.
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The annual incidence rate of STEMI had age- and biomarker-adjusted declines among men
and women (Tables 2 and 3). For men, the decline was greater in the period from 1997
through 2008 (−8.0 percent (95% CI: −10.4, −5.7) per year) than in the prior decade (−2.0
percent (95% CI: −3.4, −0.5) per year) (p<0.01). The age- and biomarker-adjusted incidence
of NSTEMI also declined over the 22-year period. Without biomarker adjustment, the rate
of decline in NSTEMI was about half that observed for STEMI.
The trends in 28-day case fatality percentages among hospitalized MI cases are shown in
Figure 2 and Table 4. The overall decline in 28-day case fatality among men for hospitalized
cases was similar in the both decades, although a greater improvement in 28-day case
fatality in the more recent decade occurred among black men in ARIC. For men the age- and
race adjusted annual percent change in 28-day case fatality for hospitalized MI was −4.4
percent (95% CI: −7.5, −1.2) per year from 1987 to 1996 and −3.3 percent (95% CI: −6.5,
−0.2) per year from 1997 to 2007 (Table 4). Among women, the significant decline in 28-
day case fatality seen from 1987 through 1996 was no longer significant in the more recent
decade.
Trends in a modified definition of MI not including biomarkers (presence of evolving
diagnostic Q wave patterns on serial electrocardiograms, or as any evidence of any
diagnostic Q wave or ST-segment elevation on any electrocardiograms and a history of chest
pain of cardiac origin) yielded similar patterns to those seen in Tables 2 and 3. Accounting
for lack of data on out-of-hospital deaths among community residents for whom neither an
informant interview or physician questionnaire was available had little effect on the overall
patterns of CHD mortality trends. Similarly, adjustment of hospitalized MI events for
missing records did not appreciably change the original trend estimates.
Discussion
We found that the age-adjusted CHD mortality rates declined among 35 to 74 year olds in
four geographically and ethnically diverse communities in the ARIC Study from 1987
through 2008. Although the event trends observed in the ARIC communities may not be
representative of the entire US, the decline in CHD mortality rate was statistically
significant for both blacks and whites in ARIC. This decline in CHD mortality in the ARIC
communities was similar to that reported from national vital statistics. 21–23 However, the
three-fold acceleration of the decline in CHD mortality rates in the most recent decade (1997
to 2008) in the ARIC communities was greater than the 2-fold acceleration of the decline in
early 2000s reported using United States statistics. 23 The Framingham Study cohort and a
community surveillance study in Worcester, Massachusetts also reported that the decline
CHD mortality and sudden cardiac death has accelerated in recent decades. 24–25
A major determinant of the accelerated decline in CHD mortality observed is the
concomitant decline in MI incidence. After accounting for shifts in biomarkers over time,
the incidence of hospitalized MI declined an average 3.8 percent per year in men and 3.5
percent per year in women. The percent declines during the most recent time period (1997
through 2008) were approximately twice those of the previous decade and were most
dramatic among blacks. Our findings corroborate those reported in the Kaiser Permanente
Northern California health care system 7 where the incidence of MI increased from 1999 to
2000, and then decreased each year thereafter through 2008. A greater decline in STEMI
compared to non-STEMI found in the Kaiser Permanente study is in agreement with the
trends in STEMI and non-STEMI we observed in the four ARIC communities. However, the
Kaiser data were not reported by ethnicity, were not adjusted for change in use of cardiac
biomarkers, and represented trends in non-validated events based solely on discharge
diagnosis codes or through billing claims.
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Recent reports from Olmsted County, Minnesota 8 and Worcester, Massachusetts 9 indicate
that trends in incidence of MI varied by the presence or absence of ST elevation. In Olmsted
County, incidence rates of STEMI declined by 41% from 1987 through 2006, whereas the
incidence rates of non-STEMI increased by a similar percentage. In Olmsted County, when
all MIs were included irrespective of the biomarker used for diagnosis, the incidence rates of
MI did not change between 1987 and 2006. In analysis restricted to those cases meeting only
CK and CK-MB criteria, they found a significant temporal decline in the incidence of MI of
about 1 percent per year. However, this method of adjustment may not adequately account
for the addition of new biomarkers and the elimination of older biomarkers in some
hospitals.
Our findings agree with a recent study of hospitalization rates among the Medicare Fee-for-
Service beneficiaries.5 From 2002 to 2007, white men experienced a 24 percent decrease in
hospitalized MI rates, whereas black men experienced a decline of 18 percent. Direct
comparisons between Medicare data and ARIC are limited because Medicare events were
non-validated, lacked a differentiation between incident and recurrent events, and were
restricted to individuals over age 65 years. However, the Medicare findings agree well with
those from the National Hospital Discharge survey showing a decline in hospitalization rates
for acute MI from 1996 to 2005 after a period of stability in rates between 1987 and 1995. 6
Our results on case fatality trends agree with previous studies reporting steady
improvements in age-and sex-adjusted mortality after MI in recent decades 7–8, although we
found the decline among women to be less consistent than that observed in men. Strengths
of our study include its population-based design, inclusion of multiple ethnically diverse
communities, standardized event validation procedures and innovative application of
standard statistical adjustment methods for accounting for shifts in biomarkers use over
time. However, conducting on-going community surveillance and validation of
hospitalizations among all residents in multiple communities over 22-years presents
challenges to maintaining comparability across time. Hospitalizations of community
residents occurring in hospitals occurring out of state are only included if the patient was
transferred to a surveillance hospital. Although this may be a source of bias in our study,
data from death certificate surveillance suggest that the relatively few out of state events
have little impact on our trend estimates. Also due to small numbers of blacks in two of the
four communities, event rates for blacks only represent those occurring in two communities.
This may limit the generalizability of our findings.
The ultimate measure of successful public health and clinical efforts to reduce the major
cause of mortality in the United States comes from community-based studies of disease
incidence rates. 26–27 ARIC findings on declining incidence trends of hospitalized MI and
out of hospital CHD death and steady improvements in 28-day case fatality, viewed together
with other reports from community based studies, large national databases, and large health
maintenance organizations, strongly support the conclusion that the past decade has seen a
new era of impact from primary prevention efforts in the United States. 5, 7–8, 28 This
conclusion could not be made 10 years ago when, although coronary heart disease mortality
rates were falling, incidence of hospitalized MI remained static 1, 29. Our novel approach to
accounting for changing diagnostic biomarkers over time adds new evidence in support of
this conclusion. Maintaining the decline in incidence of MI that has gained momentum in
the new millennium and continuing the decline in death due coronary heart disease will
require continued efforts to promote cardiovascular health at the community level.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Age- and biomarker-adjusted rate (per 1000 persons) in first hospitalized myocardial
infarction or death due to CHD without prior myocardial infarction, and age-adjusted trends
by linear or quadratic Poisson regression, men and women 35 to 74 years of age, the ARIC
Study 1987 through 2008.
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Age-adjusted 28-day case fatality percentage for hospitalized MI events, and age-adjusted
trends by linear or quadratic Poisson regression, men and women 35 to 74 years of age, the
ARIC Study 1987 through 2008.
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